“Should meaningful business development not materialize and depending on the pipeline of potential transactions, we will opportunistically buyback shares.”

In context

“ing pressure, particularly in the U.S. as the market continues to shift towards newer adult pneumococcal conjugate vaccines. We remain committed to our capital allocation priorities. We will continue to prioritize investments in our pipeline and business to drive near and long-term growth across our portfolio. We have made significant progress across our pipeline which Dean will speak to that has the potential to drive sustainable revenue growth. We are augmenting our pipeline by steering the best external science through value-enhancing business development, which we will invest in to realize the promise of these products. We continue to consider the full breadth of the business development landscape. We have ample balance sheet capacity and we will act only when science and value align. Should meaningful business development not materialize and depending on the pipeline of potential transactions, we will opportunistically buyback shares. We remain committed to our dividend with the goal of increasing it over time. To conclude, as we finish the year, we remain confident in the continued growth of our business. Global demand for our innovative medicines and vaccines remains strong and we continue to demonstrate the operational momentum and commercial execution that will enable us to deliver value to patients and shareholders now and well into the future. With that, I’d now like to turn the call over to Dean. Dean Li: Thank you, Caroline. It’s my pleasure to provide an update on our progress since the second quarter call. We have growing momentum in our pipeline across therapeutic areas, across modalities, across stages of development and across the spectrum of internal programs, established partnerships and recent business”